Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ — Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age- related macular degeneration (AMD).
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.